Patents by Inventor Martin Smrcina

Martin Smrcina has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9102628
    Abstract: The invention relates to derivatives of pyrazole 3,5-carboxylates, of general formula (I): in which R1, R2, R3, R4, R5, X, Y, V, W and n are as defined herein. The invention also relates to salts of these compounds as well as hydrates or of solvates, enantiomers, diastereoisomers and mixtures thereof. Also disclosed are the methods of preparation and application in therapeutics of compounds of formula (I).
    Type: Grant
    Filed: December 24, 2009
    Date of Patent: August 11, 2015
    Assignee: SANOFI
    Inventors: Yann Foricher, Martin Smrcina, Viviane Van Dorsselaer, Fabienne Weber
  • Patent number: 9073853
    Abstract: The present invention relates to compounds of formula 1 that are useful for the preventive or therapeutic treatment of diseases caused by abnormal activation of CXCR3 chemokines. The invention relates furthermore to a process for the preparation of said compounds, to pharmaceutical compositions containing said compounds and to novel intermediates used in the preparation of said compounds.
    Type: Grant
    Filed: June 3, 2014
    Date of Patent: July 7, 2015
    Assignee: SANOFI
    Inventors: Imre Bata, Peter Buzder-Lantos, Attila Vasas, Veronika Bartane Bodor, Gyorgy Ferenczy, Zsuzsanna Tomoskozi, Gabor Szeleczky, Sandor Batori, Martin Smrcina, Marcel Patek, Aleksandra Weichsel, David Squire Thorpe
  • Publication number: 20140288106
    Abstract: The present invention relates to compounds of formula 1 that are useful for the preventive or therapeutic treatment of diseases caused by abnormal activation of CXCR3 chemokines. The invention relates furthermore to a process for the preparation of said compounds, to pharmaceutical compositions containing said compounds and to novel intermediates used in the preparation of said compounds.
    Type: Application
    Filed: June 3, 2014
    Publication date: September 25, 2014
    Applicant: Sanofi
    Inventors: Imre BATA, Peter BUZDER-LANTOS, Attila VASAS, Veronika BARTANE BODOR, Gyorgy FERENCZY, Zsuzsanna TOMOSKOZI, Gabor SZELECZKY, Sandor BATORI, Martin SMRCINA, Marcel PATEK, Aleksandra WEICHSEL, David Squire Thorpe
  • Patent number: 8569535
    Abstract: The present invention relates to novel compounds of the formula Ia: in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, wherein the substituents are as described herein. The inventive compounds have CXCR5 inhibitory activity, and are particularly useful in treating or preventing various inflammatory diseases, such as rheumatoid arthritis, multiple sclerosis, lupus, Crohn's Disease, associated with the modulation of the human CXCR5 receptor.
    Type: Grant
    Filed: November 30, 2009
    Date of Patent: October 29, 2013
    Assignee: Sanofi
    Inventors: Thomas Joseph Caulfield, Jennifer Williford Clemens, Robert S. Francis, Brian Scott Freed, Stanly John, Tieu-Binh Le, Brian Pedgrift, Antonio Daniel Ramos, Gerard Charles Rosse, Martin Smrcina, David Squire Thorpe, William Shelly Wire, Jianhong Zhao
  • Patent number: 8268828
    Abstract: This invention is directed to a 3-(amido or sulphamido)-4-(4-substituted-azinyl)benzamide or benzsulphonamide compound as defined herein. The 3-(amido or sulphamido)-(4-substituted-azinyl)benzamide or benzsulphonamide compound is useful as a inhibitor of the chemokine receptor CxCR3, and for preventing or treating a CxCR3 chemokine receptor mediated disease or condition related thereto in a patient in need of such.
    Type: Grant
    Filed: August 6, 2010
    Date of Patent: September 18, 2012
    Assignee: Sanofi
    Inventors: David Squire Thorpe, Martin Smrcina, Dagmar Dasha Cabel
  • Patent number: 8058290
    Abstract: The disclosure relates to compounds of formula (I): which modulate the activity of proteins, particularly kinases, and to compositions containing the same, and to the use thereof as medicaments, in particular as anticancer agents.
    Type: Grant
    Filed: January 29, 2008
    Date of Patent: November 15, 2011
    Assignee: Aventis Pharma S.A.
    Inventors: Kirsten Bjergarde, Anil Nair, Marcel Patek, Martha Ackerman-Berrier, Martin Smrcina, Eric Bacque, Michel Tabart, Baptiste Ronan, Vincent Leroy, Fabrice Viviani, Mark Dodson, Catherine Souaille
  • Patent number: 7994168
    Abstract: The invention relates to substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives substituted with amino acids, and to the physiologically tolerated salts thereof, processes for their preparation and their use as medicaments.
    Type: Grant
    Filed: February 21, 2007
    Date of Patent: August 9, 2011
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Petra Lennig, Siegfried Stengelin, Thomas Klabunde, Matthias Gossel, Pavel Safar, James Spoonamore, Gregory Merriman, Joseph T Klein, Brian Whiteley, Carolina Lanter, Kenneth Bordeau, Zhaoxia Yang, Martin Smrcina
  • Patent number: 7910602
    Abstract: The invention relates to 6-amido substituted pyrazolopyridine derivatives of the formula (I) useful as inhibitors of beta-adrenergic receptor kinase 1 (?ARK-1), compositions containing such compounds and their use for the treatment and prevention of chronic heart failure, hypertension, myocardial ischemia and hepatitis C virus (HCV) infections, and for the prevention of opiate addiction.
    Type: Grant
    Filed: December 20, 2007
    Date of Patent: March 22, 2011
    Assignee: Sanofi-Aventis
    Inventors: Henning Steinhagen, Jochen Huber, Kurt Ritter, Bernard Pirard, Kirsten Bjergarde, Marcel Patek, Martin Smrcina, Linli Wei
  • Publication number: 20100305088
    Abstract: This invention is directed to a 3-(amido or sulphamido)-4-(4-substituted-azinyl)benzamide or benzsulphonamide compound as defined herein. The 3-(amido or sulphamido)-(4-substituted-azinyl)benzamide or benzsulphonamide compound is useful as a inhibitor of the chemokine receptor CxCR3, and for preventing or treating a CxCR3 chemokine receptor mediated disease or condition related thereto in a patient in need of such.
    Type: Application
    Filed: August 6, 2010
    Publication date: December 2, 2010
    Applicant: SANOFI-AVENTIS
    Inventors: David S. Thorpe, Martin Smrcina, Dagmar D. Cabel
  • Patent number: 7750005
    Abstract: The invention relates to substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives and to the physiologically tolerated salts and physiologically functional derivatives thereof. Compounds of the formula I in which the radicals have the stated meanings, and the physiologically tolerated salts thereof and processes for preparing them are described. The compounds are suitable for example as anorectic agents.
    Type: Grant
    Filed: May 21, 2008
    Date of Patent: July 6, 2010
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Stefanie Flohr, Siegfried Stengelin, Matthias Gossel, Thomas Klabunde, Pavel Safar, James Spoonamore, Martin Smrcina
  • Publication number: 20100160377
    Abstract: The invention relates to derivatives of pyrazole 3,5-carboxylates, of general formula (I): in which R1, R2, R3, R4, R5, X, Y, V, W and n are as defined herein. The invention also relates to salts of these compounds as well as hydrates or of solvates, enantiomers, diastereoisomers and mixtures thereof. Also disclosed are the methods of preparation and application in therapeutics of compounds of formula (I).
    Type: Application
    Filed: December 24, 2009
    Publication date: June 24, 2010
    Applicant: SANOFI-AVENTIS
    Inventors: Yann FORICHER, Martin SMRCINA, Viviane VAN DORSSELAER, Fabienne WEBER
  • Publication number: 20100113462
    Abstract: The present invention relates to novel compounds of the formula I: wherein in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, wherein the substituents are as described herein. The inventive compounds have CXCR5 inhibitory activity are particularly useful in treating or preventing various inflammatory diseases, such as rheumatoid arthritis, multiple sclerosis, lupus, Crohn's Disease, associated with the modulation of the human CXCR5 receptor.
    Type: Application
    Filed: November 30, 2009
    Publication date: May 6, 2010
    Applicant: SANOFI-AVENTIS
    Inventors: Thomas J. CAULFIELD, Jennifer Williford CLEMENS, Robert S. FRANCIS, Brian S. FREED, Stanly JOHN, Tieu-Binh LE, Brian PEDGRIFT, Antonio D. RAMOS, Gerard Charles ROSSE, Martin SMRCINA, David S. THORPE, William WIRE, Jianhong ZHAO
  • Patent number: 7652007
    Abstract: Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for the preparation and their use as medicaments The invention relates to substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives and to the physiologically tolerated salts and physiologically functional derivatives thereof. Compounds of the formula I in which the radicals have the stated meanings, and the physiologically tolerated salts thereof and processes for preparing them are described. The compounds are suitable for example as anorectic agents.
    Type: Grant
    Filed: February 13, 2004
    Date of Patent: January 26, 2010
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Stefanie Flohr, Siegfried Stengelin, Matthias Gossel, Thomas Klabunde, Petra Stahl, Pavel Safar, James Spoonamore, Martin Smrcina, Joseph Klein, Gregory Merriman, Brian Whiteley, Carolina Lanter, Kenneth Bordeau, Zhaoxia Yang
  • Publication number: 20080227777
    Abstract: The invention relates to 6-amido substituted pyrazolopyridine derivatives of the formula (I) useful as inhibitors of beta-adrenergic receptor kinase 1 (?ARK-1), compositions containing such compounds and their use for the treatment and prevention of chronic heart failure, hypertension, myocardial ischemia and hepatitis C virus (HCV) infections, and for the prevention of opiate addiction.
    Type: Application
    Filed: December 20, 2007
    Publication date: September 18, 2008
    Applicant: SANOFI-AVENTIS
    Inventors: Henning STEINHAGEN, Jochen HUBER, Kurt RITTER, Bernard PIRARD, Kirsten BJERGARDE, Marcel PATEK, Martin SMRCINA, Linli WEI
  • Publication number: 20080221113
    Abstract: Substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments The invention relates to substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives and to the physiologically tolerated salts and physiologically functional derivatives thereof. Compounds of the formula I in which the radicals have the stated meanings, and the physiologically tolerated salts thereof and processes for preparing them are described. The compounds are suitable for example as anorectic agents.
    Type: Application
    Filed: May 21, 2008
    Publication date: September 11, 2008
    Applicant: Sanofi-Aventis Deutschland GmbH
    Inventors: Stefanie Flohr, Siegfried Stengelin, Matthias Gossel, Thomas Klabunde, Pavel Safar, James Spoonamore, Martin Smrcina
  • Publication number: 20080182844
    Abstract: The disclosure relates to compounds of formula (I): which modulate the activity of proteins, particularly kinases, and to compositions containing the same, and to the use thereof as medicaments, in particular as anticancer agents.
    Type: Application
    Filed: January 29, 2008
    Publication date: July 31, 2008
    Applicant: AVENTIS PHARMA S.A.
    Inventors: Kirsten BJERGARDE, Anil NAIR, Marcel PATEK, Martha ACKERMAN-BERRIER, Martin SMRCINA, Eric BACQUE, Michel TABART, Baptiste RONAN, Vincent LEROY, Fabrice VIVIANI, Mark DODSON, Catherine SOUAILLE
  • Patent number: 7390814
    Abstract: Substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments The invention relates to substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives and to the physiologically tolerated salts and physiologically functional derivatives thereof. Compounds of the formula I in which the radicals have the stated meanings, and the physiologically tolerated salts thereof and processes for preparing them are described. The compounds are suitable for example as anorectic agents.
    Type: Grant
    Filed: February 13, 2004
    Date of Patent: June 24, 2008
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Stefanie Flohr, Siegfried Stengelin, Matthias Gossel, Thomas Klabunde, Pavel Safar, James Spoonamore, Martin Smrcina
  • Publication number: 20070197539
    Abstract: The invention relates to substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives substituted with amino acids, and to the physiologically tolerated salts thereof, processes for their preparation and their use as medicaments
    Type: Application
    Filed: February 21, 2007
    Publication date: August 23, 2007
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Petra Lennig, Siegfried Stengelin, Thomas Klabunde, Matthias Gossel, Pavel Safar, Martin Smrcina, James Spoonamore, Gregory Merriman, Joseph Klein, Brian Whiteley, Carolina Lanter, Kenneth Bordeau, Zhaoxia Yang
  • Patent number: 7132536
    Abstract: The present invention relates to triaza- and tetraaza-anthracenedione derivatives of the formula I, wherein A, B and R1 to R5 are as defined herein. The compounds of formula I are valuable pharmacologically active compounds. They are useful in the treatment of various disease states including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency. They upregulate the expression of the enzyme endothelial nitric oxide (NO) synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
    Type: Grant
    Filed: April 21, 2004
    Date of Patent: November 7, 2006
    Assignee: Sanofi-aventis Deutschland GmbH
    Inventors: Andreas Weichert, Hartmut Strobel, Paulus Wohlfart, Marcel Patek, Martin Smrcina, Aleksandra Weichsel
  • Patent number: 7122323
    Abstract: An apparatus and method for synthesizing a combinatorial library comprising a plurality of chemical compounds such that the chemical composition of each compound is easily tracked. The library compounds are synthesized on solid-phase supports, which are spatially arranged in frames during synthesis according to a predetermined protocol, such that each solid-phase support passes through a series of unique spatial 2D or 3D addresses by which the chemical composition of each compound may be determined at any point during synthesis. Solid-phase supports include hollow tubular-shaped lanterns and gears.
    Type: Grant
    Filed: December 11, 2002
    Date of Patent: October 17, 2006
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Marcel Patek, Safar Pavel, Martin Smrcina, Eric Wegrzyniak, Peter Strop, Gary A Flynn, Stephen A Baum